Statements (24)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:activeIngredient |
gptkb:vibegron
|
| gptkbp:approvalYear |
2020
|
| gptkbp:ATCCode |
gptkb:G04BD15
|
| gptkbp:brand |
gptkb:Gemtesa
|
| gptkbp:chemicalFormula |
C26H27F2N3O2
|
| gptkbp:countryOfOperation |
gptkb:United_States
|
| gptkbp:form |
gptkb:tablet
|
| gptkbp:genericName |
gptkb:vibegron
|
| https://www.w3.org/2000/01/rdf-schema#label |
Gemtesa
|
| gptkbp:indication |
overactive bladder
|
| gptkbp:legalStatus |
Rx-only (US)
|
| gptkbp:manufacturer |
gptkb:Urovant_Sciences
|
| gptkbp:mechanismOfAction |
beta-3 adrenergic receptor agonist
|
| gptkbp:pregnancyCategory |
not assigned (US)
|
| gptkbp:prescriptionStatus |
prescription only
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
diarrhea headache urinary retention |
| gptkbp:bfsParent |
gptkb:Vibegron
gptkb:vibegron |
| gptkbp:bfsLayer |
7
|